Literature DB >> 26643499

[Evidence-based treatment of psychosis associated with Parkinson's disease].

R Haussmann1, M Bauer2, M Donix2.   

Abstract

Psychotic symptoms in Parkinson's disease are frequent phenomena and are often associated with an immense burden for caregivers, increased risk of nursing home placement and mortality. Treatment of psychotic disorders associated with Parkinson's disease often poses a therapeutic dilemma and necessitates a differentiated risk-benefit assessment as both the reduction of antiparkinsonian drugs and use of antipsychotic drugs can result in deterioration of motor functions. This article gives an overview of relevant clinical aspects and highlights the pharmacological evidence-based treatment options.

Entities:  

Keywords:  Parkinson’s disease; Pharmacotherapy; Psychotic disorders; Substance-induced psychoses; Treatment

Mesh:

Substances:

Year:  2016        PMID: 26643499     DOI: 10.1007/s00115-015-4438-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  43 in total

1.  Clozapine and risperidone treatment of psychosis in Parkinson's disease.

Authors:  T Ellis; M E Cudkowicz; P M Sexton; J H Growdon
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

2.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

3.  Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.

Authors:  Bernard Ravina; Karen Marder; Hubert H Fernandez; Joseph H Friedman; William McDonald; Diane Murphy; Dag Aarsland; Debra Babcock; Jefferey Cummings; Jean Endicott; Stewart Factor; Wendy Galpern; Andrew Lees; Laura Marsh; Mark Stacy; Katrina Gwinn-Hardy; Valerie Voon; Christopher Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

4.  Longitudinal outcome of Parkinson's disease patients with psychosis.

Authors:  S A Factor; P J Feustel; J H Friedman; C L Comella; C G Goetz; R Kurlan; M Parsa; R Pfeiffer
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

5.  Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

Authors:  Kelvin L Chou; Susan Messing; David Oakes; Peter D Feldman; Alan Breier; Joseph H Friedman
Journal:  Clin Neuropharmacol       Date:  2005 Sep-Oct       Impact factor: 1.592

6.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

Review 7.  Dementia associated with Parkinson's disease.

Authors:  Murat Emre
Journal:  Lancet Neurol       Date:  2003-04       Impact factor: 44.182

8.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

9.  Early dopaminergic drug-induced hallucinations in parkinsonian patients.

Authors:  C G Goetz; C Vogel; C M Tanner; G T Stebbins
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  Ophthalmologic features of Parkinson's disease.

Authors:  V Biousse; B C Skibell; R L Watts; D N Loupe; C Drews-Botsch; N J Newman
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

View more
  1 in total

Review 1.  [Causes of visual hallucinations in Parkinson's disease].

Authors:  Nico J Diederich
Journal:  Nervenarzt       Date:  2021-08-03       Impact factor: 1.297

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.